Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.

Clearmind Medicine testified at the FDA's history-making psychedelic hearing in Washington, D.C. on September 14, 2026, after receiving an invitation from the agency to address patient access. Chief of Global Impact Mary-Elizabeth Gifford briefed a federal listening panel alongside senior officials from the FDA's psychiatry division, SAMHSA, NIDA, ARPA-H, and the Veterans Health Administration, with approximately 1,800 participants attending in person and virtually. MEAI, Clearmind's non-hallucinogenic neuroplastogen candidate for Alcohol Use Disorder, is currently being evaluated in an FDA-approved Phase 2a clinical trial at Yale University Medical School and Johns Hopkins University.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.